Lightlake Therapeutics Inc. Appoints New Board Member
17 April 2012 - 4:32PM
Marketwired
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or
"Lightlake"), an early stage biopharmaceutical company developing
modern addiction treatments based on its expertise using opioid
antagonists, announced today that it has appointed Kevin A. Pollack
to the Company's Board of Directors.
Mr. Pollack is a Managing Director at Paragon Capital, an
investment firm based in New York City, and also the President of
Short Hills Capital LLC, a FINRA broker-dealer based in New York
City. He previously specialized in corporate finance and mergers
and acquisitions at Banc of America Securities, and he also
practiced corporate, securities and mergers and acquisitions law at
Sidley Austin (formerly Brown & Wood), a global law firm. Mr.
Pollack graduated magna cum laude from The Wharton School of the
University of Pennsylvania and holds J.D. and M.B.A. degrees from
Vanderbilt University, where he graduated with Beta Gamma Sigma
honors.
"I am absolutely delighted to join Lightlake's Board," said Mr.
Pollack. "The Company's highly experienced management team, cutting
edge research in addiction treatment and strong patent portfolio
position Lightlake extremely well for future growth, and I look
forward to utilizing my biopharmaceutical, business, finance, legal
and public markets expertise to enhance the value of the
Company."
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical
company aiming to build a platform of biopharmaceutical solutions
to common addictions and related disorders. Currently, the Company
is focused on providing a safe, effective and simple treatment for
patients who are obese or overweight as a result of Binge Eating
Disorder in addition to those patients suffering from Bulimia
Nervosa. Lightlake recently acquired patents that will allow it to
widen its product pipeline to address patients with addictions to
opioid painkillers, methadone, cocaine and amphetamine. The Company
anticipates launching a development program for each of these
purposes in the future.
Safe Harbor
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward- looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
Investor Contact: Mr. Kevin Fickle President NUWA Group LLC Tel:
+1-925-330-8315 Email: kevin@nuwagroup.com Company Contact: Dr.
Roger Crystal Lightlake Therapeutics Inc. Tel: +44(0)-207-034-1943
Email: roger.crystal@lightlaketherapeutics.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024